Cardiac complications of chemotherapy: Role of prevention

Current Treatment Options in Cardiovascular Medicine

Volumn 16, Issue 6, 2014, Pages

  Magnano, Laura Carola ^a   Martínez Cibrian, Nuria ^a   Andrade González, Xavier ^a   Bosch, Xavier ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer; Cardiotoxicity; Chemotherapy; Prevention

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MITOXANTRONE; RAZOXANE; TELMISARTAN; TOXIC SUBSTANCE; TRASTUZUMAB; VALSARTAN;

ACUTE GRANULOCYTIC LEUKEMIA; ALCOHOL CONSUMPTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CELL DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); DNA POLYMORPHISM; DRUG ABUSE; DRUG ADMINISTRATION; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART EJECTION FRACTION; HEART FAILURE; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIMARY PREVENTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SEDENTARY LIFESTYLE; SMOKING; THROMBOEMBOLISM;

EID: 84901272876     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-014-0312-7     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013;34:1102-11.
3. Eschenhagen T, Force T, Ewer MS, Keuenaer GW, Suter TM, Anker SD. CV side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13:1-10.
4. Lipshultz S, Lipsitz S, Sallen S, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-36. (Pubitemid 46179451)
5. Wouters K, Kremer L, Herman E, Lipshultz S.Protecting against anthracyclines-induce myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561-78. (Pubitemid 43899624)
6. .•• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639-42. Study describing the molecular mechanism of anthracycline-induced cardiotoxicity. The results open the possibility to identify patients at high-risk of cardiotoxicity, and of developing less cardiotoxic drugs
7. Khouri M, Douglas P, Mackey J, et al. Cancer therapy-induced cardiac toxicity in early breast cancer. Circulation. 2012;126:2749-63.
8. Zver S, Zadnik V, Bunc M, Rogel P, Cernelc P, Kozelj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007;85:408-14. (Pubitemid 47457450)
9. García-Alvarez A, García-Albéniz X, Esteve J, Rovira M, Bosch X. Cardiotoxicity of tyrosine-kinase-targeting drugs. Cardiovasc Hematol Agents Med Chem. 2010;8:11-21.
10. .• Curigliano G, Cardinale D, Suter T, et al. CV toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidlines. Ann Oncol. 2012;23 suppl 7:vii155-66. An actualized clinical guideline based on current evidence
11. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of LV ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61:77-84.
12. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013. doi:10.1161/CIR.0b013e31829e8776.
13. .• Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, Jones LW. Modulation of anthracyclineinduced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation. 2011;124:642-50. Good review on the beneficial effects of exercise on anthracycline-induced cardiotoxicity
14. Chicco A, Hydock D, Schneider C, Hayward R. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol. 2006;100:519-27. (Pubitemid 43671603)
15. .• Smith L, Cornelius V, Plummer C, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337. Good systematic review on anthracycline cardiac toxicity showing that there is not sufficiently robust evidence to support clear evidence-based recommendations on different anthracycline treatment regimens or for routine use of cardiac protective agents or liposomal formulations, and that there is a need to improve cardiac monitoring in oncology trials
16. .• Van Dalen E, Michiels E, Caron H, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;3, CD005006. Cochrane meta-analysis of all clinical trials comparing doxorubicin vs epirubicin, and conventional doxorubicin vs liposomal- encapsulated doxorubicin
17. .•• Van Dalen E, Caron H, Dickinson H, et al. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;6, CD003917. Cochrane meta-analysis of clinical trials performed until 2010 to prevent chemotherapy-induced cardiac toxicity. Only dexrazoxane is efficacious in preventing heart damage in patients treated with anthracyclines, and that there is no evidence of a lower response rate to cancer therapy. Negative effects on progression-free survival were not identified
18. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicintreated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-53. (Pubitemid 38886649)
19. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11:950-61.
20. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25:493-500. (Pubitemid 350002954)
21. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. Leukemia. 2010;24:355-70.
22. Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res. 2000;25:597-603.
23. Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ, Cunningham JN, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583-6. (Pubitemid 35278509)
24. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001;414:71-8. (Pubitemid 32174877)
25. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-8. (Pubitemid 41103593)
26. .•• Cardinale D, Colombo A, Sandri M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-81. First study to prove the efficacy of a troponin-guided strategy of myocardial prevention with enalapril in patients in highrisk patients submitted to high-dose chemotherapy (Pubitemid 44901520)
27. Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker Valsartan on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisolone. Cancer. 2005;104:2492-8. (Pubitemid 41691573)
28. Cadeddu C, Piras A, Mantovani G, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487e.1-7.
29. Santos DL, Moreno AJ, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol. 2002;185:218-27. (Pubitemid 36062795)
30. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37:837-46. (Pubitemid 39222076)
31. .•• Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258-62. Study demonstrating the cardioprotective effects of carvedilol on anthracycline-induced LV dysfunction (Pubitemid 44855419)
32. El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE. Protective effect of carvedilol on adriamicyn-induced LV dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012;18:607-13.
33. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective parallel-group, randomized, controlled study with 36 month follow-up. Am J Hematol. 2010;85:894-907.
34. .• Bosch X, Rovira M, Sitges M, et al. Enalapril and carvedilol for preventing chemotherapy-induced LV systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of LV dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61:2355-62. First study performed in patients with malignant hemopathies using enalapril and carvedilol at the time of hospital admission as a primordial prevention strategy, and showing a beneficial effect on chemotherapy-induced LV systolic dysfunction. Patients with acute leukemia treated with more intense chemotherapy regimens and including anthracyclines benefited the most from this prevention strategy
35. Riad A, Bien S, Westermann D, et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res. 2009;69:695-9.
36. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384-90.
37. Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988-9.
38. Blanco J, Leisenring W, Gonzalez-Covarrubias V, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112:2789-95. (Pubitemid 351969225)
39. .• Visscher H, Ross CJD, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30:1422-8. One of the biggest genetic studies performed to find predictors of anthracycline-induced cardiotoxicity. 3000 single-nucleotide polymorphisms were evaluated in 156 patients, and the results replicated in two other cohort of patients